205 related articles for article (PubMed ID: 36357156)
1. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
3. Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis.
Pagnoux C; Berti A
Expert Opin Pharmacother; 2023; 24(11):1269-1281. PubMed ID: 37204027
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
8. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
9. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis.
Bloom JL; Langford CA; Wechsler ME
Rheum Dis Clin North Am; 2023 Aug; 49(3):563-584. PubMed ID: 37331733
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
Doubelt I; Pulenzas N; Carette S; Pagnoux C;
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
[TBL] [Abstract][Full Text] [Related]
12. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab for eosinophilic granulomatosis with polyangiitis.
Cottu A; Groh M; Desaintjean C; Marchand-Adam S; Guillevin L; Puechal X; Beaumesnil S; Lazaro E; Samson M; Taille C; Durel CA; Diot E; Nicolas S; Guilleminault L; Ebbo M; Cathebras P; Dupin C; Yildiz H; Belfeki N; Pugnet G; Chauvin P; Jouneau S; Lifermann F; Martellosio JP; Cottin V; Terrier B;
Ann Rheum Dis; 2023 Dec; 82(12):1580-1586. PubMed ID: 37550002
[TBL] [Abstract][Full Text] [Related]
14. [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].
Hellmich B; Holle J; Moosig F
Z Rheumatol; 2022 May; 81(4):286-299. PubMed ID: 35075511
[TBL] [Abstract][Full Text] [Related]
15. Churg-Strauss syndrome.
Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
17. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.
Puéchal X; Pagnoux C; Baron G; Quémeneur T; Néel A; Agard C; Lifermann F; Liozon E; Ruivard M; Godmer P; Limal N; Mékinian A; Papo T; Ruppert AM; Bourgarit A; Bienvenu B; Geffray L; Saraux JL; Diot E; Crestani B; Delbrel X; Sailler L; Cohen P; Le Guern V; Terrier B; Groh M; Le Jeunne C; Mouthon L; Ravaud P; Guillevin L;
Arthritis Rheumatol; 2017 Nov; 69(11):2175-2186. PubMed ID: 28678392
[TBL] [Abstract][Full Text] [Related]
18. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Pagnoux C; Groh M
Expert Rev Clin Immunol; 2016 Oct; 12(10):1059-67. PubMed ID: 27191665
[TBL] [Abstract][Full Text] [Related]
19. Biologics for eosinophilic granulomatosis with polyangiitis.
Caminati M; Maule M; Bello F; Emmi G
Curr Opin Allergy Clin Immunol; 2023 Feb; 23(1):36-43. PubMed ID: 36413432
[TBL] [Abstract][Full Text] [Related]
20. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
